Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression

Lithium, a mood stabilizer and common adjunctive treatment for refractory depression, shares overlapping mechanisms of action with ketamine and enhances the duration of ketamine’s antidepressant actions in rodent models at sub-therapeutic doses. Yet, in a recent clinical trial, lithium co-treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, J. Blair, Yates, Clarissa G., Morath, Brooke A., Van De Wakker, Sam K., Yates, Nathanael J., Butters, Kim, Frye, Mark A., McGee, Sean L., Tye, Susannah J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617175/
https://www.ncbi.nlm.nih.gov/pubmed/34824208
http://dx.doi.org/10.1038/s41398-021-01716-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617175/
https://www.ncbi.nlm.nih.gov/pubmed/34824208
http://dx.doi.org/10.1038/s41398-021-01716-w

Ejemplares similares